"Cancer"

The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).

In recent years, scientists have begun to look at "transforming" cancer cells from life-threatening bad actors to help fight cancer.

New research confirms that the innovative treatment Zolbetuximab, in combination with chemotherapy, is highly effective in the treatment of gastric cancer, especially in advanced stages, and is expected to be a potential new treatment for patients with gastric cancer.

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

According to data from an ongoing Phase I/Ib clinical trial (NCT04374877), an innovative IL-27 inhibitor called SRF388 has shown promising results in the treatment of locally advanced or advanced non-small cell lung cancer (NSCLC), which undoubtedly brings new hope for the treatment of lung cancer patients in general!

A new generation of oral selective estrogen receptor degrader, elastostat, has shown promise in clinical studies over standard second-line treatments such as fulvestrant for the treatment of patients with metastatic hormone receptor-positive breast cancer.

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

The Dana-Farber Cancer Institute, founded in 1947, is a specialist cancer hospital affiliated with Harvard Medical School, a federally designated comprehensive cancer treatment centre in the United States, and has produced one Nobel Laureate in medicine.